A recent study also showed promising results with a combination drug containing an aptamer targeting PDGF beta and siRNA targeting STAT3, leading to reduced growth in both in vitro and in vivo glioma models, and utilized subcutaneous xenografts for in vivo experiments [41]. This evidence concerns the gene STAT3 and central nervous system cancer.